Live Recordings (Sleep Medicine Trends 2026)-02 Strategies for Optimal Management of RLS

Video Transcription

Video Summary

The speaker reviews updated diagnosis and management of restless legs syndrome (RLS), emphasizing that many patients self-diagnose (or use “Dr. AI”), so clinicians should confirm true RLS and rule out mimics. Treatment is generally reserved for symptoms ≥3 times/week. A key early step is screening for obstructive sleep apnea, since untreated apnea can make RLS difficult to control—especially before considering opioids.<br /><br />They highlight common RLS aggravators, especially medications like duloxetine, and stress asking patients what they are doing to self-treat, as some attempt unsafe remedies. The 2024 guidelines are framed as practice-changing: dopamine agonists are no longer first-line due to augmentation and withdrawal difficulties, and alpha-2-delta ligands (notably pregabalin) are strongly recommended, usually dosed in the evening rather than multiple daytime doses.<br /><br />Iron evaluation and replacement are central, with correct fasting morning labs and consideration of oral then IV iron (often effective with hematology support). For refractory cases, low-dose extended-release opioids can be effective with relatively low misuse risk but high stigma and logistical barriers. Nonpharmacologic options include an FDA-approved peroneal nerve stimulator, vibration plates, weighted blankets/sleep pods, compression boots, and percussion devices. The talk also touches on CBT/insomnia management, special populations, and a case of pregabalin allergy mistaken for dopamine withdrawal.

Keywords

restless legs syndrome

2024 RLS guidelines

dopamine agonist augmentation

alpha-2-delta ligands

pregabalin evening dosing

iron studies and replacement

obstructive sleep apnea screening

low-dose extended-release opioids